Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine最新文献

筛选
英文 中文
Relationships of Walking and non-Walking Physical Activities in Daily Life with Cognitive Function and Physical Characteristics in Male Patients with Mild Chronic Obstructive Pulmonary Disease. 男性轻度慢性阻塞性肺疾病患者日常步行和非步行运动与认知功能和身体特征的关系
IF 2
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine Pub Date : 2022-01-01 DOI: 10.1177/11795484221146374
Shojiro Egoshi, Jun Horie, Akinori Nakagawa, Yuriko Matsunaga, Shinichiro Hayashi
{"title":"Relationships of Walking and non-Walking Physical Activities in Daily Life with Cognitive Function and Physical Characteristics in Male Patients with Mild Chronic Obstructive Pulmonary Disease.","authors":"Shojiro Egoshi,&nbsp;Jun Horie,&nbsp;Akinori Nakagawa,&nbsp;Yuriko Matsunaga,&nbsp;Shinichiro Hayashi","doi":"10.1177/11795484221146374","DOIUrl":"https://doi.org/10.1177/11795484221146374","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is accompanied by dyspnea on exertion due to airflow limitation caused by bronchial stenosis, with afflicted patients being less physically active. Therefore, physical activity is important for disease management.</p><p><strong>Objectives: </strong>This study aimed to examine the relationships of walking and non-walking physical activities with cognitive function or physical characteristics of patients with mild COPD in a community without respiratory rehabilitation.</p><p><strong>Design: </strong>Cross-sectional study.</p><p><strong>Data sources and methods: </strong>We included 40 male patients (mean age, 75.7 ± 6.7 years) with stable mild COPD. A three-axis accelerometer was used to evaluate walking and non-walking physical activities in daily life. Cognition, respiratory function, skeletal muscle mass, limb muscle strength, exercise capacity, and health-related quality of life were assessed.</p><p><strong>Results: </strong>Regarding daily exercise amount (metabolic equivalents × hours; Ex), 87.5% of the participants had walking activities of 0-2 Ex, while 67.5% had non-walking activities of 1-3 Ex. Walking activity was significantly correlated with cognitive function (<i>P</i> < .05), walking distance (<i>P</i> < .01), and health-related quality of life (<i>P</i> < .05), but not with muscle mass. However, non-walking activity was significantly correlated with the body mass index (<i>P</i> < .05), muscle mass (<i>P</i> < .05), and walking distance (<i>P</i> < .01), but not with cognitive function. Moreover, the relationship between non-walking activity and health-related quality of life was weaker than the corresponding relationship with walking activity.</p><p><strong>Conclusion: </strong>In patients with mild COPD, walking and non-walking physical activities showed different relationships with cognitive function and physical characteristics. The findings suggest that self-management of such patients requires maintenance of both walking and non-walking activities in a balanced manner.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"16 ","pages":"11795484221146374"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/ec/10.1177_11795484221146374.PMC9791294.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10453376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Erratum. 错误:错误。
IF 2
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine Pub Date : 2022-01-01 DOI: 10.1177/11795484221127555
Rosie S Jones, Patricia S Smith, Paul H Berg, Amparo de la Peña, Paul P Cook, Imad Shawa, Kathleen M Kioussopoulos, Yu Hu, Robert J Schott
{"title":"Erratum: Erratum.","authors":"Rosie S Jones,&nbsp;Patricia S Smith,&nbsp;Paul H Berg,&nbsp;Amparo de la Peña,&nbsp;Paul P Cook,&nbsp;Imad Shawa,&nbsp;Kathleen M Kioussopoulos,&nbsp;Yu Hu,&nbsp;Robert J Schott","doi":"10.1177/11795484221127555","DOIUrl":"https://doi.org/10.1177/11795484221127555","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/11795484221119316.].</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"16 ","pages":"11795484221127555"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755543/pdf/10.1177_11795484221127555.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10405433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complicated Case of Multidrug-Resistant Tuberculosis with Multiple Comorbidities, Successfully Treated After Several Treatment Modifications. 多药耐药结核病合并多种合并症的复杂病例,经多次修改治疗成功。
IF 2
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine Pub Date : 2022-01-01 DOI: 10.1177/11795484221142468
Benedreky Leo, Heni Retnowulan
{"title":"Complicated Case of Multidrug-Resistant Tuberculosis with Multiple Comorbidities, Successfully Treated After Several Treatment Modifications.","authors":"Benedreky Leo,&nbsp;Heni Retnowulan","doi":"10.1177/11795484221142468","DOIUrl":"https://doi.org/10.1177/11795484221142468","url":null,"abstract":"<p><p>A 59-year-old man with relapsed pulmonary TB developed rifampin resistance. He presented with chronic untreated hepatitis B, which developed into liver cirrhosis, type 2 diabetes with diabetic retinopathy, and osteoarthritis of right knee. His initial MDR regimen included levofloxacin, cycloserine, bedaquiline, linezolid, and high-dose isoniazid. He developed episodes of linezolid-induced myelosuppression, resulting in temporary discontinuation and dose reduction, and ultimately, substitution of linezolid. On the seventh month of treatment, he developed severe depression with visual hallucination, resulting in cycloserine dose reduction. We maintained the principle of at least 4 active drugs throughout his treatment. He was considered cured after 26 months of treatment.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"16 ","pages":"11795484221142468"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/b8/10.1177_11795484221142468.PMC9761204.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10424567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Prevalence, Presentation and Outcomes of Silent Hypoxemia in COVID-19 COVID-19无症状低氧血症的流行、表现和结局
IF 2
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine Pub Date : 2022-01-01 DOI: 10.1177/11795484221082761
Amélia Ribeiro, M. Mendonça, C. Sabina Sousa, M. Trigueiro Barbosa, M. Morais‐Almeida
{"title":"Prevalence, Presentation and Outcomes of Silent Hypoxemia in COVID-19","authors":"Amélia Ribeiro, M. Mendonça, C. Sabina Sousa, M. Trigueiro Barbosa, M. Morais‐Almeida","doi":"10.1177/11795484221082761","DOIUrl":"https://doi.org/10.1177/11795484221082761","url":null,"abstract":"Dyspnea is reported in a minority of patients affected by coronavirus disease 2019 (COVID-19). Even patients with pneumonia can present hypoxemia without any respiratory distress, a phenomenon known as “silent” or “happy hypoxemia”. During the current pandemic there were only a few studies conducted on this subject and these were quite heterogeneous. Therefore, the prevalence of “silent hypoxemia” varied substantially. While studies did not show a clear tendency of “silent hypoxemia” to poorer outcomes compared to hypoxemia presenting with dyspnea, several showed that patients with “silent hypoxemia” are not protected from poor outcomes either. There is a need for a uniform definition of “silent hypoxemia”, in order to better guide clinicians and investigators. More studies are needed to shed light on the mechanisms of “silent hypoxemia”, as well as its presentation and influence in the disease's progression and outcomes, so as to better assist physicians in the care of COVID-19 patients.","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"46 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86700533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Evaluation of Blood Biochemistry and Cardiopulmonary status of Hospitalized Covid-19 Patients in 3 Months Post Discharged Follow up Survey. 新冠肺炎住院患者出院后3个月血液生化及心肺状况随访调查
IF 2
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine Pub Date : 2022-01-01 DOI: 10.1177/11795484221119332
Saeed Nateghi, Elahe Hesari, Fariba Mansouri, Majid Akrami, Mandana Pourian, Arezoo Khosravani, Fatemeh Taghizadeh, Samaneh Akbarpour, Neda Faraji
{"title":"Evaluation of Blood Biochemistry and Cardiopulmonary status of Hospitalized Covid-19 Patients in 3 Months Post Discharged Follow up Survey.","authors":"Saeed Nateghi,&nbsp;Elahe Hesari,&nbsp;Fariba Mansouri,&nbsp;Majid Akrami,&nbsp;Mandana Pourian,&nbsp;Arezoo Khosravani,&nbsp;Fatemeh Taghizadeh,&nbsp;Samaneh Akbarpour,&nbsp;Neda Faraji","doi":"10.1177/11795484221119332","DOIUrl":"https://doi.org/10.1177/11795484221119332","url":null,"abstract":"<p><strong>Background: </strong>The new coronavirus causes systemic inflammation and damage to various organs. So, this study aimed to follow up patients with COVID -19 after recovery for three months by performing cardiac, pulmonary and laboratory tests.</p><p><strong>Materials and methods: </strong>This was a prospective cohort study of COVID-19 patients who were discharged from Baharloo Hospital. The diagnosis of COVID-19 was confirmed by PCR or long CT scan. Inclusion criteria were age over 18 years and patients with more than 50% of pulmonary involvement in lung CT scan. The patients were called to Baharloo hospital three months after recovery and were examined for cardiac, pulmonary and blood tests.</p><p><strong>Result: </strong>Our study included 178 participants with mean age of 55.70, and 50.6% of them were male. Among pulmonary factors in the hospital, 71.9%, 15.7%,1.7%,19.1% and 53.4% had positive GGO, consolidation, reverse halo sign, traction bronchiectasis and vascular enlargement, respectively. After three months follow up, percentage of patients who had reticulation, honeycombing, fibrotic brand and bullae were 12%, 1.1%,8.4% and 0%, respectively. The Mean values of FVC and FEV1 were reported 4.21 and 3.01, respectively. Among Cardiac factors, positive PVC, PAC and mean Pap were decreased after three months. Only Growth in myalgia and Decreased sense of taste were statistically significant. Also, D dimer, UA protein, PMN, Ferritin CRP, PMN, LDH and HB amounts had decreased significantly.</p><p><strong>Conclusion: </strong>Our study indicated that in addition to pulmonary changes, rapid damage to other organs and the occurrence of cardiac symptoms and changes in laboratory result were also reported in patients recovered from COVID-19.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"16 ","pages":"11795484221119332"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/0c/10.1177_11795484221119332.PMC9791284.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9549752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. 抗血管生成素-2抗体LY3127804在肺炎合并疑似或确诊COVID-19住院患者的随机、双盲、安慰剂对照临床试验中的疗效和安全性
IF 2
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine Pub Date : 2022-01-01 DOI: 10.1177/11795484221119316
Rosie S Jones, Patricia S Smith, Paul H Berg, Amparo de la Peña, Paul P Cook, Imad Shawa, Kathleen M Kioussopoulos, Yu Hu, Robert J Schott
{"title":"Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19.","authors":"Rosie S Jones,&nbsp;Patricia S Smith,&nbsp;Paul H Berg,&nbsp;Amparo de la Peña,&nbsp;Paul P Cook,&nbsp;Imad Shawa,&nbsp;Kathleen M Kioussopoulos,&nbsp;Yu Hu,&nbsp;Robert J Schott","doi":"10.1177/11795484221119316","DOIUrl":"https://doi.org/10.1177/11795484221119316","url":null,"abstract":"<p><strong>Background: </strong>Severe cases of coronavirus disease 2019 (COVID-19) are characterized by progressive respiratory failure and the development of acute respiratory distress syndrome (ARDS), with high mortality rates for patients requiring mechanical ventilation. Levels of the vascular growth factor Angiopoietin 2 (Ang2) in plasma have been strongly correlated with increased ARDS risk in patients with pneumonia or sepsis. The intent of this study was to determine whether LY3127804, an anti-Ang2 monoclonal antibody, could reduce the need for mechanical ventilation among patients admitted to the hospital with pneumonia and presumed or confirmed COVID-19.</p><p><strong>Methods: </strong>Patients admitted to hospital with confirmed pneumonia, presumed or confirmed COVID-19, and infiltrates on chest imaging and/or oxygen saturation of ≤ 95% on room air were stratified by age group (< 65 years and ≥ 65 years), sex, and site and randomly assigned 1:1 within each stratum to receive either LY3127804 (20 mg/kg) or placebo on Day 1 and possibly on Day 15. The primary end point for this study was number of days in which a patient did not require a ventilator over the 28-day study period.</p><p><strong>Results: </strong>Interim analysis assessed study futility after 95 randomized patients had 28-day data available and showed no benefit of LY3127804 in reducing the number of ventilator days over placebo. The study was subsequently terminated.</p><p><strong>Conclusion: </strong>LY3127804 treatment did not decrease the need for ventilator usage in patients hospitalized with pneumonia and presumed or confirmed COVID-19.</p><p><strong>Clinicaltrialsgov identifier: </strong>NCT04342897.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"16 ","pages":"11795484221119316"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/35/10.1177_11795484221119316.PMC9382233.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10377257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Detection of Anti-SARS-CoV-2 Nucleocapsid and Spike Antibodies in Patients with Coronavirus Disease 2019 in Japan 日本2019冠状病毒病患者抗sars - cov -2核衣壳抗体和刺突抗体检测
IF 2
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine Pub Date : 2021-07-09 DOI: 10.1177/11795484221075492
H. Furukawa, S. Oka, T. Higuchi, Miho Yamaguchi, S. Uchiyama, T. Koiwa, Moriyuki Nakama, Masaaki Minegishi, H. Nagai, S. Tohma
{"title":"Detection of Anti-SARS-CoV-2 Nucleocapsid and Spike Antibodies in Patients with Coronavirus Disease 2019 in Japan","authors":"H. Furukawa, S. Oka, T. Higuchi, Miho Yamaguchi, S. Uchiyama, T. Koiwa, Moriyuki Nakama, Masaaki Minegishi, H. Nagai, S. Tohma","doi":"10.1177/11795484221075492","DOIUrl":"https://doi.org/10.1177/11795484221075492","url":null,"abstract":"OBJECTIVES Coronavirus Disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Serological testing for anti-SARS-CoV-2 nucleocapsid (N) antibodies (Abs) and anti-SARS-CoV-2 spike (S) Abs is performed to detect prior COVID-19 infection. It is still controversial which antibodies are the most sensitive and specific, and which can be detected earliest after infection. Here, we evaluated the results of serological tests of anti-SARS-CoV-2 N and S Abs in Japan. METHODS Symptomatic COVID-19 patients (n = 84) and control patients with rheumatoid arthritis (n = 93) were recruited at Tokyo National Hospital. Anti-SARS-CoV-2 N and S Abs were measured by commercial electrochemiluminescence immunoassays. RESULTS The fraction of patients positive for anti-SARS-CoV-2 N and S Abs was highest >14 days after symptom onset. The frequency of anti-SARS-CoV-2 S Ab positivity at this time (80.4%) tended to be slightly but not significantly lower than anti-SARS-CoV-2 N Ab positivity (84.8%). Optimized cut-off levels for anti-SARS-CoV-2 N and S Ab positivity were lower than the manufacturer's recommended cut-off levels. Using multiple linear regression analyzes with anti-SARS-CoV-2 N and S Abs, we created an Ab-index with high sensitivity. CONCLUSION To increase the sensitivity of serological diagnostic tests for COVID-19, it is suggested that both anti-SARS-CoV-2 N and S Abs should be measured and cut-off levels decreased.","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"179 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2021-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80085997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
COVID-19 Related Cardiovascular Comorbidities and Complications in Critically Ill Patients: A Systematic Review and Meta-analysis. 危重患者COVID-19相关心血管合并症和并发症:系统回顾和荟萃分析
IF 2
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine Pub Date : 2021-01-01 DOI: 10.1177/1179548421992327
Michael Koeppen, Peter Rosenberger, Harry Magunia
{"title":"COVID-19 Related Cardiovascular Comorbidities and Complications in Critically Ill Patients: A Systematic Review and Meta-analysis.","authors":"Michael Koeppen,&nbsp;Peter Rosenberger,&nbsp;Harry Magunia","doi":"10.1177/1179548421992327","DOIUrl":"https://doi.org/10.1177/1179548421992327","url":null,"abstract":"<p><strong>Objective: </strong>This systematic-review and meta-analysis aimed to assess the prevalence of cardiovascular comorbidities and complications in ICU-admitted coronavirus disease 2019 (COVID-19) patients.</p><p><strong>Data sources: </strong>PubMed and Web of Science databases were referenced until November 25, 2020.</p><p><strong>Data extraction: </strong>We extracted retrospective and prospective observational studies on critically ill COVID-19 patients admitted to an intensive care unit. Only studies reporting on cardiovascular comorbidities and complications during ICU therapy were included.</p><p><strong>Data synthesis: </strong>We calculated the pooled prevalence by a random-effects model and determined heterogeneity by Higgins' <i>I</i> <sup>2</sup> test.</p><p><strong>Results: </strong>Of the 6346 studies retrieved, 29 were included in this review. The most common cardiovascular comorbidity was arterial hypertension (50%; 95% confidence interval [CI], 0.42-058; <i>I</i> <sup>2</sup> = 94.8%, low quality of evidence). Among cardiovascular complications in the ICU, shock (of any course) was most common, being present in 39% of the patients (95% CI, 0.20-0.59; <i>I</i> <sup>2</sup> = 95.6%; 6 studies). Seventy-four percent of patients in the ICU required vasopressors to maintain target blood pressure (95% CI, 0.58-0.88; <i>I</i> <sup>2</sup> = 93.6%; 8 studies), and 30% of patients developed cardiac injury in the ICU (95% CI, 0.19-0.42; <i>I</i> <sup>2</sup> = 91%; 14 studies). Severe heterogeneity existed among the studies.</p><p><strong>Conclusions: </strong>Cardiovascular complications are common in patients admitted to the intensive care unit for COVID-19. However, the existing evidence is highly heterogeneous in terms of study design and outcome measurements. Thus, prospective, observational studies are needed to determine the impact of cardiovascular complications on patient outcome in critically ill COVID-19 patients.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"15 ","pages":"1179548421992327"},"PeriodicalIF":2.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548421992327","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9178803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Spotlight on New Antibiotics for the Treatment of Pneumonia. 聚焦治疗肺炎的新型抗生素。
IF 2
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine Pub Date : 2020-12-20 eCollection Date: 2020-01-01 DOI: 10.1177/1179548420982786
Alessandro Russo
{"title":"Spotlight on New Antibiotics for the Treatment of Pneumonia.","authors":"Alessandro Russo","doi":"10.1177/1179548420982786","DOIUrl":"https://doi.org/10.1177/1179548420982786","url":null,"abstract":"<p><p>In the last years, the presence of multidrug-resistant (MDR) Gram-negative (like <i>Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii</i>) and Gram-positive bacteria (mostly methicillin-resistant <i>Staphylococcus aureus</i>) was worldwide reported, limiting the options for an effective antibiotic therapy. For these reasons, inappropriate antimicrobial therapy and delayed prescription can lead to an unfavorable outcome, especially in patients with pneumonia. New antibiotics approved belong to classes of antimicrobials, like beta-lactams with or without beta-lactamase inhibitors, aminoglycosides, oxazolidinones, quinolones, and tetracyclines, or based on new mechanisms of action. These new compounds show many advantages, including a broad spectrum of activity against MDR pathogens, good lung penetration, safety and tolerability, and finally the possibility of intravenous and/or oral formulations. However, the new antibiotics under development represent an important possible armamentarium against difficult-to-treat strains. The safety and clinical efficacy of these future drugs should be tested in clinical practice. In this review, there are reported characteristics of newly approved antibiotics that represent potential future options for the treatment of respiratory tract infections, including those caused by multidrug-resistant bacteria. Finally, the characteristics of the drugs under development are briefly reported.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"14 ","pages":"1179548420982786"},"PeriodicalIF":2.0,"publicationDate":"2020-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548420982786","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38802172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Early Experience With Methylprednisolone on SARS-CoV-2 Infection in the African American Population, a Retrospective Analysis. 甲基强的松龙治疗非裔美国人SARS-CoV-2感染的早期经验:回顾性分析
IF 2
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine Pub Date : 2020-12-14 eCollection Date: 2020-01-01 DOI: 10.1177/1179548420980699
Subodh J Saggi, Sridesh Nath, Roshni Culas, Seema Chittalae, Aaliya Burza, Maya Srinivasan, Rishard Abdul, Benjamin Silver, Alnardo Lora, Ishmam Ibtida, Tanuj Chokshi, Violeta Capric, Ammar Mohamed, Samrat Worah, Jie OuYang, Patrick Geraghty, Angelika Gruessner, Moro O Salifu
{"title":"Early Experience With Methylprednisolone on SARS-CoV-2 Infection in the African American Population, a Retrospective Analysis.","authors":"Subodh J Saggi, Sridesh Nath, Roshni Culas, Seema Chittalae, Aaliya Burza, Maya Srinivasan, Rishard Abdul, Benjamin Silver, Alnardo Lora, Ishmam Ibtida, Tanuj Chokshi, Violeta Capric, Ammar Mohamed, Samrat Worah, Jie OuYang, Patrick Geraghty, Angelika Gruessner, Moro O Salifu","doi":"10.1177/1179548420980699","DOIUrl":"10.1177/1179548420980699","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease-19 (COVID-19) is associated with acute kidney injury (AKI) and acute respiratory distress syndrome (ARDS) with high mortality rates. In African American (AA) populations, COVID-19 presentations and outcomes are more severe. NIH and Interim WHO guidelines had suggested against the use of corticosteroids unless in clinical trials until the recent publication of the RECOVERY trial. Here, we analyzed the treatment effect of methylprednisolone on patients with AKI and ARDS during the initial 2 months of COVID-19 and detail the learning effect within our institution.</p><p><strong>Methods: </strong>Between March 1 and April 30, 2020, 75 AA patients met our inclusion criteria for ARDS and AKI, of which 37 had received corticosteroids. Twenty-eight-day mortality, improvement in PaO<sub>2</sub>/FiO<sub>2</sub> ratio, and renal function were analyzed. The impact of methylprednisolone treatment was assessed with multivariable methods.</p><p><strong>Results: </strong>Survival in the methylprednisolone group reached 51% at 21 days compared to 29% in the non-corticosteroid group (<i>P</i> < .001). Methylprednisolone improved the likelihood of renal function improvement. PaO<sub>2</sub>/FiO<sub>2</sub> ratio in the methylprednisolone group improved by 73% compared to 45% in the non-corticosteroid group (<i>P</i> = .01). Age, gender, BMI, preexisting conditions, and other treatment factors did not show any impact on renal or PaO<sub>2</sub>/FiO<sub>2</sub> ratio improvement. The use of anticoagulants, the month of treatment, and AKI during hospitalization also influenced outcomes.</p><p><strong>Conclusion: </strong>In AA COVID-19 positive patients with ARDS and AKI, IV methylprednisolone lowered the incidence of mortality and improved the likelihood of renal and lung function recovery. Further investigation with a randomized control trial of corticosteroids is warranted.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"14 ","pages":"1179548420980699"},"PeriodicalIF":2.0,"publicationDate":"2020-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548420980699","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38784493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信